Yet another effect of RARS on cancers involves gene fusion between RARS and mitotic arrest deficient 1-like protein 1 (MAD1L1), which induces the proliferation of nasopharyngeal cancer cell lines and their chemo- and radio-resistance (Zhong et al., 2018). The gene discussed is MAD1L1; the disease is nasopharyngeal carcinoma.